Full Press Release Details
Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer
Texas (May 24, 2022) - Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing
novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the "Company"
or "Anebulo"), today announced the appointment of Dr. Kenneth Cundy, Ph.D. as Chief Scientific Officer of the Company. Dr.
Cundy is a highly respected scientist having innovated and developed multiple therapeutics throughout his career.
"I am thrilled to welcome Ken to the Anebulo team, his expertise
in drug development comes at an opportune time for the Company as we advance ANEB-001 through human clinical trials for acute cannabinoid
intoxication," said Simon Allen, Chief Executive Officer of Anebulo. "Ken's broad experience in drug discovery, preclinical
and clinical development, and product approval spans more than 30 years with various companies and includes blockbuster drugs such as
Gilead's HIV drug tenofovir and the filing of more than 15 INDs and 6 NDAs."
In addition to his extensive drug development experience, Dr. Cundy has
a proven record of successful innovation, with 50 issued U.S. and over 100 international patents to his name. He also has extensive experience
in interacting with partners, the FDA, and international regulatory agencies.
"I look forward to leading Anebulo's research and development
initiatives as we advance ANEB-001 into later stage clinical trials," said Dr. Cundy. "I am particularly impressed by the
compelling pharmacology of our lead program and the exciting data generated to date. Together, with the rest of the Anebulo team, we have
the opportunity to deliver a groundbreaking therapy for ACI to treat this serious and rapidly growing unmet need."
to joining Anebulo, Dr. Cundy served as Chief Scientific Officer at CohBar, Inc., a publicly-traded biotechnology company developing
therapeutics targeting chronic and age-related diseases, where he built and expanded a technology platform around novel analogs
of regulatory peptides encoded in the mitochondrial genome, advanced their lead program from pre-clinical to successful clinical proof
of concept for NASH and obesity, and secured these innovations with multiple issued patents. Before CohBar, Dr. Cundy was Chief Scientific
Officer at XenoPort, Inc., a biopharmaceutical company focused on therapeutics for neurological disorders. He was coinventor of XenoPort's
approved drug Horizant , and led efforts from discovery to development and approval for the treatment of postherpetic
neuralgia and restless legs syndrome in the US and Japan. Previously, Dr. Cundy held various positions at Gilead Sciences, Inc. where
he was a key contributor to the development of Gilead's antiviral franchise, including blockbuster drugs such as Viread ,
Hepsera , Vistide , and Tamifu . He was coinventor of Gilead's transformational blockbuster
drug tenofovir disoproxil, approved and marketed as single (Viread ), double (Truvada ), triple (Atripla )
and quadruple (Complera and Stribild ) therapies for HIV. Dr. Cundy started his scientific career at Sterling
Winthrop, a pharmaceutical division of Eastman Kodak Company, where he led efforts to design and evaluate novel formulation technologies
exploiting Kodak's historical capabilities. He was coinventor of Nanocrystal technology, a novel formulation approach
for poorly soluble drugs that was subsequently used in many approved drug products. Dr. Cundy received a B.S. in pharmacy from the University
of Manchester and was registered as a pharmacist in the United Kingdom before earning a Ph.D. in pharmaceutical sciences from the University
of Kentucky and postdoctoral training in Biochemistry at the University of California, Berkeley.
Anebulo Pharmaceuticals, Inc.
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid
intoxication and substance abuse disorder. Its lead product candidate, ANEB-001, is currently in a Phase 2 clinical trial (www.clinicaltrials.gov/ct2/show/NCT05282797)
to evaluate its utility in reversing the negative effects of acute cannabinoid intoxication within one hour of administration. This trial
is being run in the Netherlands by the Centre for Human Drug Research (CHDR). ANEB-001 is a competitive antagonist at the human cannabinoid
receptor type 1 (CB1). For further information about Anebulo, please visit www.anebulo.com.
press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as "anticipate,"
"expect," "intend," "may," "will," "should" and other comparable terms, involve
risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include
statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as
the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are
not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing
the company's product candidates, and those described in Anebulo Pharmaceutical's most recent annual report on Form 10-K
and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking
statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking
statements to reflect changed conditions.
Pharmaceuticals, Inc.
of Investor Relations and Public Relations